Bovine viral diarrhoea virus (BVDV) causes significant economic losses to the cattle industry worldwide. Previously, we demonstrated that heme oxygenase-1 (HO-1) can inhibit BVDV replication via an unknown molecular mechanism. To elucidate the mechanism involved, we assess whether the HO-1 downstream metabolites carbon monoxide (CO), biliverdin (BV) and iron affect BVDV replication. We treated Madin-Darby bovine kidney (MDBK) cells with an exogenous CO donor, CORM-2. We found that CORM-2 but not its inactive form (iCORM-2) inhibited BVDV replication in a dose-dependent and time duration-dependent manner, suggesting a CO-specific mediation of the CORM-2 antiviral effect. Direct incubation of BVDV with high-dose CORM-2 reduced virus titres, suggesting that CORM-2 attenuates BVDV growth by both physically inactivating virus particles in the extracellular environment and affecting intracellular BVDV replication, but mainly via an intracellular mechanism. Exogenous BV treatment, both post-infection and co-incubation with BVDV, inhibited BVDV replication in a dosedependent manner, indicating that BV has potent antiviral activity against BVDV. Direct incubation of BVDV with BV had no significant effect on virus titres, indicating that BV is not virucidal and attenuates BVDV growth by affecting intracellular BVDV replication. Furthermore, BV was found to affect BVDV penetration but not attachment. However, increased iron via addition of FeCl 3 did not interfere with BVDV replication. Collectively, the results of the present study demonstrate that the HO-1 metabolites BV and CO, but not iron, inhibit BVDV replication. These findings not only provide new insights into the molecular mechanism of HO-1 inhibition of BVDV replication but also suggest potential new control measures for future BVDV infection.
INTRODUCTION
Bovine viral diarrhoea (BVD) is one of the most economically important viral diseases affecting the cattle industry worldwide [1, 2] . BVD is caused by bovine viral diarrhoea virus (BVDV), which is a positive-strand RNA virus belonging to the genus Pestivirus, family Flaviviridae. The family Flaviviridae includes four genera, the classical flaviviruses, the pestiviruses, the hepatitis C viruses and the pegiviruses. Pestiviruses, comprising BVDV, border disease virus and classical swine fever virus, are important animal pathogens [2] . BVDV infections have resulted in from $10 to $40 milllion losses per million calves in the United States alone [3, 4] . In addition, it has been reported that BVDV was highly prevalent in Chinese pig herds [5] . Therefore, it is imperative to study BVDV biology for the development of antiviral strategies to combat BVDV infection.
Heme oxygenase-1 (HO-1) is a microsomal enzyme that catalyses the first and rate-limiting step in the degradation of heme to carbon monoxide (CO), biliverdin (BV) and free iron [6, 7] . HO-1 has numerous biological functions, including anti-oxidant, anti-inflammatory, anti-apoptotic and anti-proliferative properties and plays an important role in host defence against microbial infection [8] . Several recent studies have demonstrated significant antiviral properties of HO-1. Specifically, up-regulation of HO-1 was shown to suppress infection by porcine reproductive and respiratory syndrome virus (PRRSV) [9, 10] , enterovirus [11] , influenza virus [12] , hepatitis C virus (HCV) [13, 14] , hepatitis B virus (HBV) [15] and human immunodeficiency virus (HIV) [16] . A previous study by us showed that over-expression or induction of HO-1 expression inhibits BVDV replication [17] . However, the molecular mechanism underlying HO-1 inhibition of BVDV replication remains unknown.
In this study, we explored the effect of HO-1 downstream metabolites CO, BV and iron on BVDV infection and uncovered an intracellular molecular mechanism that can explain the observed HO-1-driven cytoprotective effect. For the first time, we demonstrate that the HO-1 metabolites CO and BV significantly inhibit BVDV replication; however, iron, another HO-1 product, did not show any inhibitory effect on BVDV infection. These findings will be helpful for developing potential new BVDV control measures.
RESULTS
CORM-2 inhibits BVDV replication in MDBK cells in a dose-dependent manner Our previous research showed that HO-1 can suppress BVDV replication [17] . However, the molecular mechanism of HO-1 inhibition of BVDV replication is unclear. To explore this antiviral mechanism, we first investigated the effect of CO on BVDV infection using an exogenous CO donor, tricarbonyldichlororuthenium (II) dimer (CORM-2). Madin-Darby bovine kidney (MDBK) cells were treated with CORM-2 or inactive CORM-2 (iCORM-2) at different concentrations 1 h after BVDV infection. The expression of viral RNA and protein, and BVDV production were analysed by quantitative reverse transcriptase PCR (RT-qPCR), western blot and virus titres at 24 h post-infection (h p.i.). As shown in Fig. 1(a, c) , treatment of MDBK cells with 50-150 µM CORM-2 markedly decreased the intracellular expression levels of BVDV mRNA and NS5B protein in a dose-dependent manner. There was a 22, 43 and 65 % decrease in the abundance of BVDV RNA from MDBK cells treated with 50, 100 and 150 µM CORM-2 compared with untreated cells, respectively (Fig. 1a) .
Consistent with intracellular BVDV RNA and NS5B protein expression, CORM-2 treatment also decreased virus titres Cells and culture supernatants were collected at 24 h p.i. RT-qPCR, western blot and TCID 50 were used to determine the intracellular BVDV RNA (a), NS5B protein (c), extracellular BVDV RNA (d) and virus titres in the supernatants (b). Data are expressed as mean±SD of three independent experiments. P values were calculated using ANOVA. *P<0.05; **P<0.01; ***P<0.001. (Fig. 1b) and the levels of BVDV RNA (Fig. 1d) in the supernatants in a dose-dependent manner. BVDV progeny titres in 50, 100 and 150 µM CORM-2-treated MDBK cells decreased by 0.40-log, 0.70-log and 1.00-log compared with untreated cells, respectively (Fig. 1b) , and the amount of extracellular viral RNA was reduced by 20, 36 and 56 % compared with untreated cells, respectively (Fig. 1d) . However, iCORM-2, an inactive molecule which cannot release CO, had no significant effect on BVDV replication (Fig. 1 ). There were no significant cytotoxic effects at the CORM-2 concentrations used (data not shown).
CORM-2 inhibits BVDV replication in MDBK cells in a time duration-dependent manner To further confirm the effect of CORM-2 on BVDV replication, MDBK cells were treated with 150 µM CORM-2 or iCORM-2 1 h after BVDV infection. Supernatants and cells were harvested at the indicated times, and then virus titres and viral gene expression were examined. As shown in Fig. 2 , CORM-2 inhibited BVDV replication in MDBK cells in a time duration-dependent manner. Treatment with CORM-2 considerably decreased the expression levels of intracellular BVDV RNA (Fig. 2a) and protein (Fig. 2c) , and also reduced virus titres (Fig. 2b ) and the levels of BVDV RNA (Fig. 2d) in the supernatants, compared with untreated cells. Expression levels of intracellular viral RNA in CORM-2-treated cells were decreased by 54, 42 and 9.3 % at 24, 36 and 48 h p.i., respectively (Fig. 2a) . Virus titres in the supernatants decreased by 1.125-log, 0.81-log and 0.26-log (Fig. 2b) , and BVDV RNA copies in the supernatants were reduced by 44, 28 and 21 %, respectively (Fig. 2d) .
CORM-2 inhibits BVDV replication of different titres
To demonstrate whether CO could inhibit replication of different titres of BVDV, MDBK cells were infected with BVDV at different m.o.i. values for 1 h and then treated with either (Fig. 3a) . Virus titres in the supernatants decreased by 1.125-log, 0.88-log and 0.70-log ( Fig. 3b) , and BVDV RNA copies in the supernatants were reduced by 42, 33 and 25 %, respectively (Fig. 3d ).
CORM-2 of high dose is directly virucidal to BVDV
To determine whether CORM-2 affects BVDV infectivity after direct contact with the virus, BVDV was diluted in medium containing either CORM-2 or iCORM-2 at different concentrations and incubated for 1 h at 37 C. Virus titres were determined in MDBK cells. Treatment of MDBK cells with 50 or 100 µM CORM-2 did not have significant effect on BVDV titres, and iCORM-2 also had no obvious effect on BVDV titres (Fig. 4) . However, virus titres in the supernatants decreased by 0.34-log from MDBK cells treated with 150 µM CORM-2 compared with untreated cells (Fig. 4) .
BV inhibits BVDV replication in MDBK cells in a dose-dependent manner
To determine the effect of BV on BVDV replication, MDBK cells were incubated with different doses of BV 1 h after BVDV infection. Expression of viral RNA and protein, and BVDV production were then analysed by RT-qPCR, western blot and virus titres at 36 h p.i. Results showed that the dose-dependent increase of BV was parallel with a 30, 60 and 80.7 % reduction in the amount of intracellular BVDV RNA (Fig. 5a ), NS5B protein (Fig. 5c) , and a 0.62-log, 1.00-log and 1.25-log reduction in the BVDV progeny titres (Fig. 5b) , and a 50, 76 and 86 % reduction in the BVDV RNA copies of supernatants ( Fig. 5d ) from MDBK cells treated with 50, 100 and 150 µM BV compared with untreated cells, respectively. To further demonstrate the effect of BV on BVDV replication, MDBK cells were co-incubated with different concentrations of BV and BVDV for 1 h at 37 C, and then these MDBK cells were incubated with different concentrations of fresh BV for 35 h. As expected, BV co-incubation with BVDV also significantly prevented BVDV replication based on the substantial reduction of levels of intracellular BVDV RNA (34, 59, 84 %) (Fig. 5e ), NS5B protein (Fig. 5g ) and progeny titres (1.00-log, 1.37-log, 1.75-log) (Fig. 5f) , and BVDV RNA copies in the supernatants (60, 78, 86 %) (Fig. 5h) . These results showed that BV inhibited BVDV infection in a dose-dependent manner. There were no significant cytotoxic effects at the BV concentrations used (data not shown).
BV attenuates BVDV growth kinetics
Because treatment with BV inhibited BVDV replication, we next evaluated whether BV treatment attenuates BVDV growth kinetics. MDBK cells were incubated with 100 µM BV at 1 h after BVDV infection at an m.o.i. of 0.05. Expression of viral RNA and BVDV production were then analysed by RT-qPCR and virus titres at the indicated time point. As shown in Fig. 6(a-c) , BV treatment resulted in significantly lower BVDV RNA and progeny virus production at 12-60 h p.i. compared to the control group. There was a 78, 71, 57, 42 and 29 % decrease in the abundance of intracellular BVDV RNA (Fig. 6a) , a 2.42-log, 1.13-log, 1.04-log, 0.46-log and 0.50-log reduction in the BVDV progeny titres (Fig. 6b) , and a 72, 72, 66, 38 and 33 % reduction in the BVDV RNA copies of supernatants (Fig. 6c ) from MDBK cells treated with BV at 12, 24, 36, 48 and 60 h p.i., respectively.
To investigate if the effect of inhibition of BV on viral growth is BVDV titre-dependent, a similar experiment as that described above was performed. MDBK cells were incubated with 100 µM BV at 1 h after BVDV infection at an m. o.i. of 1. As shown in Fig. 6(d-f) , BV treatment of MDBK cells also significantly decreased the expression level of intracellular BVDV RNA (69, 57, 43 and 20 %, Fig. 6d ) and virus titres (1.25-log, 1.09-log, 0.85-log and 0.29-log, Fig. 6e) , and BVDV RNA copies (76, 81, 52 and 23 %, Fig. 6f ) in the supernatants at 12, 24, 36 and 48 h p.i., respectively, compared to the control group.
BV is not directly virucidal to BVDV To investigate whether BV is able to reduce virus infectivity after direct contact with BVDV, virus inocula were incubated with BV at various concentrations up to 150 µM for 1 h at 37 C. Virus titres were then determined in MDBK cells. There was no significant difference in the virus titres between virus treated with mock and virus treated with BV (data not shown), indicating that BV does not affect virus infectivity at the concentrations used in this study.
BV attenuation of BVDV growth is dependent on BVDV penetration but not attachment To investigate whether BV affects virus entry of the BVDV life cycle, the kinetics of the antiviral activity of BV against BVDV were analysed with time-of-addition assays. The results showed that BV did not have an obvious inhibitory effect on the expression levels of intracellular BVDV RNA and BVDV NS5B protein, as well as virus titres and BVDV RNA copies in the supernatants when it was added immediately after the temperature shift ( Fig. 7a-d) . However, BV reduced the expression levels of viral RNA and protein, and BVDV production in a dosedependent manner after MDBK cells were treated with BV at 37 C for 2 h (Fig. 7e-h ) and 6 h ( Fig. 7i-l) . There was a 20, 28 and 46 decrease in the abundance of intracellular BVDV RNA (Fig. 7e) , a 0.5-log, 0.75-log and 0.98-log reduction in the BVDV progeny titres (Fig. 7f) , and a 18, 29 and 37 % reduction in the BVDV RNA copies of supernatants (Fig. 7h ) from MDBK cells treated with 50, 100 and 150 µM BV, respectively, at 37 C for 2 h compared with that of the control group. Similarly, there was a 25, 54 and 70 % decrease in the abundance of intracellular BVDV RNA (Fig. 7i) , a 0.88-log, 1.25-log and 1.5-log reduction in the BVDV progeny titres (Fig. 7j) , and a 37, 60 and 80 % reduction in the BVDV RNA copies of supernatants (Fig. 7l ) from MDBK cells treated with 50, 100 and 150 µM BV, respectively, at 37 C for 6 h compared with that of the control group.
Iron does not affect BVDV replication
To explore the effects of iron on BVDV replication, we tried to mimic an intracellular iron effect by adding iron III chloride solution (FeCl 3 ) to MDBK cells 1 h after BVDV infection. Expression of viral RNA and protein, and BVDV On: Sun, 13 Jan 2019 13:58:54 C, and then these MDBK cells were incubated with different concentrations of fresh BV for 35 h. RT-qPCR, western blot and TCID 50 were used to determine the intracellular BVDV RNA (e), NS5B protein (g), extracellular BVDV RNA (h) and virus titres in the supernatants (f). Data are expressed as mean±SD of three independent experiments. P values were calculated using ANOVA. **P<0.01; ***P<0.001. production were analysed by RT-qPCR, western blot and virus titres at 36 h p.i. Results showed that addition of FeCl 3 did not affect NS5B protein expression or BVDV mRNA expression or progeny virus titre (Fig. 8) .
DISCUSSION
Our previous study demonstrated that HO-1 could inhibit BVDV replication [17] . However, the molecular mechanisms underlying this action were not clear. Several studies have reported that one of the metabolites of HO-1, namely CO, BV or iron, exhibits anti-infection activity [13, 18, 19] .
To identify whether the anti-BVDV activities of HO-1 could be mediated by any of the metabolites of HO-1, MDBK cells were first treated with an exogenous CO donor, CORM-2. The results showed that CORM-2 but not iCORM-2 could significantly inhibit BVDV replication in MDBK cells in a dose-dependent ( Fig. 1) and time duration-dependent manner (Fig. 2) , suggesting a CO-specific mediation of the CORM-2 antiviral effect. We further assessed the potential virucidal effect of CORM-2. Direct incubation of BVDV with 50 or 100 µM CORM-2 had no effect on BVDV titres, while treatment with 150 µM CORM-2 reduced virus titres in the supernatants (Fig. 4) , indicating that high-dose CORM-2 is directly virucidal to BVDV. Therefore, the current data suggest that CORM-2 attenuates BVDV growth by both physically inactivating virus particles in the extracellular environment (Fig. 4) and affecting intracellular BVDV replication, but mainly via an intracellular mechanism (Figs 1, 2 and 3 ). Chung and colleagues reported that CORM enhances bacterial clearance during cecal ligation and puncture (CLP)-induced polymicrobial sepsis via a direct bactericidal effect [20] . Exposure to CO suppresses the pathogenesis of experimental cerebral malaria [18] . Conversely, exposure to exogenous CO promotes murine plasmodium liver infection [21] . Similarly, raising CO levels via CORM-2 treatment of cells also facilitates Kaposi sarcoma herpesvirus (KSHV) infection [22] . However, treatment of Dengue virus (DENV)-infected cells with CO donor did not interfere with DENV protein synthesis and RNA replication, indicating that CO did not mediate the inhibitory effects of HO-1 induction on DENV replication [23] .
Two reports have addressed whether BV can inhibit HCV replication [13, 24] . Exogenous BV treatment, both postinfection and co-incubation with BVDV, significantly inhibits BVDV replication in MDBK cells in a dose-dependent manner (Fig. 5) , indicating that BV has potent antiviral activity against BVDV. In addition to our data, BV has been also reported to inhibit replication of DENV [23] , human herpes virus type 6 [25] and HIV [26] . These data suggest that BV might have broad-spectrum antiviral activity. However, treatment of mice with exogenous BV promotes murine plasmodium liver infection [21] , indicating the differences in the effectiveness of BV against different pathogen infections. It has been speculated that BV might interfere with cellular processes specific for replication of certain viruses [13, 25] . Direct incubation of BVDV with BV had no significant effect on virus titres, indicating that BV is not virucidal and attenuates BVDV growth by affecting intracellular BVDV replication (Figs 5 and 6 ). Next, we attempted to identify the stages of BVDV infection that were impacted by BV. The results showed that BV did not have an obvious inhibitory effect on BVDV growth when it was added immediately after the temperature shift (Fig. 7a-d) , but BV attenuated BVDV growth in a dose-dependent manner after MDBK cells were treated with BV at 37 C for 2 h (Fig. 7e-h ) and 6 h (Fig. 7i-l) . These results suggest that BV might have no effect on BVDV attachment but does inhibit BVDV penetration into MDBK cells.
Iron has been shown to suppress replication of HCV [19, 24, 27, 28] . However, our results showing that FeCl 3 did not significantly interfere with BVDV replication (Fig. 8) are in contrast to previous reports. Lehmann and colleagues reported that neither FeCl 3 nor lactoferrin reduces HCV replication as measured by the luciferase assay [13] . Tseng and colleagues reported also that FeCl 3 does not mediate the inhibitory effects of HO-1 induction on DENV replication [23] . These observations are consistent with our data.
In summary, the present study demonstrates that the HO-1 metabolites BV and CO, but not iron, inhibit BVDV replication. CO-specific mediation of the CORM-2 anti-BVDV effect occurs both by a direct virucidal activity and by affecting intracellular BVDV replication, but mainly via C. After the cells were rinsed three times with ice-cold PBS, they were cultured at 37 C in the presence of various concentrations of BV for 0 h (a-d), 2 h (eh) or 6 h (i-l). Cells and culture supernatants were collected at 24 h p.i. RT-qPCR, western blot and TCID 50 were used to determine the intracellular BVDV RNA (a, e, i), NS5B protein (c, g, k), extracellular BVDV RNA (d, h, l) and virus titres in the supernatants (b, f, j). Data are expressed as mean±SD of three independent experiments. P values were calculated using ANOVA. **P<0.01, ***P<0.001.
an intracellular mechanism. BV-mediated attenuation of BVDV infection targets BVDV penetration into MDBK cells rather than physically inactivating virus particles in the extracellular environment. These findings not only provide new insights into the molecular mechanism underlying the antiviral effect of the stress-responsive protein HO-1 during BVDV infection but also suggest potential new control measures for future BVDV infection.
METHODS
Cells, viruses and reagents MDBK cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Life Technologies) supplemented with 10 % FBS and 1 % antibiotic-antimycotic (Life Technologies) at 37 C and 5 % CO 2 . BVDV strain Oregon C24V (CVCC no. AV69) was propagated on MDBK cells and stored at À80 C.
CORM-2, BV, FeCl 3 and cobalt protoporphyrin IX cobalt chloride (CoPP, a classical HO-1 inducer) were purchased from Sigma. iCORM-2 was prepared by incubating CORM-2 dissolved in DMSO for 24 h at 37 C in a 5 % CO 2 humidified atmosphere to liberate CO.
Cell viability assay
The cell viability assay was performed as described previously [17] with the following modifications. MDBK cells were plated in 96-well plates at a density of 1Â10 4 cells per well. After confluent monolayers had formed, cells were treated with different doses of CORM-2 or BV for 48 h. Then, 10 µl Cell Counting Kit-8 (CCK-8; Beyotime) reagent was added to each well of the 96-well plate containing 100 µl fresh DMEM medium according to the manufacturer's instructions and incubated for 2 h at 37 C. The absorbance was detected at 450 nm using an Epoch Microplate Spectrophotometer (BioTek Instruments) to calculate the cell viability. Results were expressed as relative to the optical density of wells containing untreated control cells defined as 100 % viability.
RNA isolation and RT-qPCR
Total RNA was extracted from MDBK cells or supernatants using TRIzol reagent (Invitrogen) and reverse transcribed using the Primescript RT reagent Kit (TaKaRa) according to the manufacturer's instructions. qPCR was performed on a Step One Plus real-time PCR system (Applied Biosystems) using FastStart Universal SYBR green master (Roche), and forward and reverse primers for the RNA of BVDV as described previously [17] . Beta-2-microglobulin (B2M) mRNA was used as an internal reference.
For supernatant BVDV RNA detection, a plasmid bearing a 357 bp fragment of the BVDV 5¢ untranslated region sequence was used to generate a standard curve. Absolute RNA quantities of supernatants were calculated by normalization to the standard curve as described previously [17] .
Western blot analysis
Western blotting was performed as described previously [9, 10] . Briefly, MDBK cells were lysed and the cellular proteins were separated by SDS-PAGE and transferred onto a PVDF membrane. The PVDF membrane was probed with one of the following primary antibodies: mouse anti-HO-1 polyclonal antibodies at a 1 : 1000 dilution and mouse anti-NS5B of BVDV polyclonal antibodies at a 1 : 1000 dilution produced in our laboratory, anti-a-tubulin antibody at a 1 : 5000 dilution (Abcam, catalogue no. ab7750), and then with HRP-conjugated anti-mouse IgG at a 1 : 2000 dilution (Jackson, catalogue no. 111-035-003) as the secondary antibody. Immunolabelled proteins were visualized using ECL reagent (Pierce).
BVDV entry assay BVDV entry assays were performed as previously described [29] with the following modifications. MDBK cells were initially challenged with BVDV at an m.o.i. of 0.05 diluted in medium containing different concentrations of BV for 3 h at 4 C. After the cells were rinsed three times with ice-cold PBS, they were cultured at 37 C in the presence of various concentrations of BV for 0, 2 or 6 h. The cells were then rinsed three times with PBS and incubated until 24 h p.i. at 37 C. The supernatants were harvested for virus titration and BVDV RNA detection, and cells were collected for RTqPCR and western blot analysis.
Virus titration
Virus progeny production was determined by titration as described previously [17] . Briefly, MDBK cells were trypsinized and seeded in 96-well plates 24 h before virus infection. Virus supernatants were prepared through serial dilutions and 100 µl of solution was added to each well in replicates of eight. Six days after infection, the TCID 50 was calculated by the Reed-Muench method.
Statistical analysis
All experiments were performed with at least three independent replicates. The results were analysed using either Student's t test for comparisons between two groups or oneway ANOVA if more groups were tested against a control group. A P value <0.05 was considered to be statistically significant.
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